We are using cookies in order to facilitate your navigation on this website. You can read about how we use cookies and how to manage them here. By continuing to navigate on this website or clicking on the button, you accept our cookie notice and related Privacy Policy.
I accept the use of cookies
Molecular Partners
  • Partnering
  • Careers
  • Contact Us
  • About Us
  • Our DARPin® Platform
  • Our Approach
  • Pipeline
  • Investors
    • Share Information
    • Analyst Coverage
    • News Releases
    • Investor & Scientific Documents
    • General Meetings
    • Governance & Compliance
    • Financial Calendar & Events
    • Investor Contact
    • Register for Email News
  • News
  • Home
  • About Us
  • Our DARPin® Platform
  • Our Approach
  • Pipeline
  • Investors
      « Back
    • Investors
    • Share Information
    • Analyst Coverage
    • News Releases
    • Investor & Scientific Documents
    • General Meetings
    • Governance & Compliance
    • Financial Calendar & Events
    • Investor Contact
    • Register for Email News
  • News
  • Partnering
  • Careers
  • Contact Us

News

News

European Media Contact

Thomas Schneckenburger
thomas.schneckenburger@molecularpartners.com
Tel: +41 44 755 5728

U.S. Media Contact

Tom Donovan
tom@tenbridgecommunications.com
Tel: +1 857 559 3397

Press Releases

April 2021

Molecular Partners Shares New Preclinical Data from its AML-Focused CD3 T-Cell Engager Program, CD40 Product Candidate MP0317, and Other Novel Immuno-oncology Approaches at AACR

April 2021

Molecular Partners Announces First Patient Dosed in a Phase 2 Clinical Trial of Ensovibep in COVID-19 Patients

March 2021

Molecular Partners Publishes Invitation to Annual General Meeting 2021

View All News >>

  • Cookie Notice
  • Privacy & Disclaimer
  • Contact Us

© 2021 Molecular Partners.